Npce 2025 tutorials for pharm tech.
01/09/2025
π Pharmaceutical Preparations (Liquid & Semi-Solid Dosage Forms)
---
1. Mixtures
Definition:
Liquid oral dosage forms containing one or more active ingredients dissolved, suspended, or dispersed in a suitable vehicle.
Types of Mixtures
Homogeneous mixtures
Solute is completely dissolved in the solvent.
Uniform throughout, no shaking required.
Examples: Paracetamol mixture, Sodium chloride solution.
Heterogeneous mixtures
Solute is not completely dissolved; particles remain suspended or dispersed.
Require shaking before use.
Examples: Magnesium trisilicate mixture, Chalk mixture.
Subtypes of Mixtures
1. Simple mixtures (solutions) β soluble drugs dissolved (e.g., Paracetamol mixture).
2. Suspension mixtures β insoluble solids dispersed (e.g., Antacid suspensions).
3. Emulsion mixtures β oil + water stabilized by emulsifier (e.g., Cod liver oil emulsion).
4. Effervescent mixtures β release COβ on contact with water (e.g., Sodium citrate mixture).
5. Aromatic mixtures β flavored to improve palatability (e.g., Aromatic spirit of ammonia).
6. Sediment mixtures β settle on standing, redispersed by shaking (e.g., Chalk mixture).
7. Linctuses β thick, viscous, soothing mixtures for cough (e.g., Simple linctus).
---
2. Syrups
Definition: Concentrated aqueous solution of sugar (usually sucrose 60β70%) with or without medicinal substances.
Functions: sweetening, masking unpleasant taste, vehicle, mild preservative.
Types of Syrups
1. Simple syrup β only sugar + water.
2. Medicated syrup β contains active drug (e.g., Diphenhydramine syrup).
3. Flavored syrup β pleasant taste, used as vehicle (e.g., Syrup of orange, cherry syrup).
Preservatives Used in Syrups
Benzoic acid / Sodium benzoate
Parabens (Methylparaben, Propylparaben)
Alcohol (10β15%)
Sweetening Agents
Natural: Sucrose, glucose, fructose, honey.
Artificial: Saccharin, aspartame, sorbitol.
---
3. Linctuses
Definition: Viscous, sweetened liquid oral dosage forms, usually containing syrup or honey, designed to relieve throat irritation or cough.
Characteristics:
High viscosity β soothing effect.
Administered in small doses (5β10 mL).
Examples: Simple linctus, Codeine linctus.
Preservatives: Same as syrups (benzoic acid, parabens, alcohol).
---
4. Liniments
Definition: Liquid or semi-liquid external preparations applied to the skin with rubbing.
Types:
1. Counter-irritant liniments (e.g., Methyl salicylate liniment).
2. Analgesic liniments (e.g., Turpentine liniment).
3. Soothing/emollient liniments (e.g., Camphor liniment).
Preservatives: Alcohol (also acts as solvent and antiseptic).
---
5. Lotions
Definition: Liquid external preparations applied without rubbing, usually by dabbing or spraying.
Uses: Cooling, soothing, cleansing.
Examples: Calamine lotion, Benzyl benzoate lotion.
Preservatives: Chlorocresol, phenol, alcohol, parabens.
---
6. Creams
Definition: Semi-solid emulsions for external application.
Types
1. Oil-in-water (O/W) creams β non-greasy, water washable, cooling (e.g., Hydrocortisone cream).
2. Water-in-oil (W/O) creams β greasy, protective (e.g., Cold cream).
Preservatives: Parabens, benzyl alcohol, chlorocresol.
---
7. Ointments
Definition: Semi-solid external preparations using greasy bases.
Characteristics: Protective, occlusive.
Examples: Sulfur ointment, Zinc oxide ointment.
Preservatives: Rarely needed (greasy bases are self-preserving).
---
8. Pastes
Definition: Semi-solid preparations with high content of insoluble powders (25β50%).
Examples: Zinc oxide paste, Salicylic acid paste.
Characteristics: Stiffer than ointments, protective.
---
9. Gels
Definition: Semi-solid, jelly-like systems formed from polymers in water or alcohol.
Examples: Metronidazole gel, Diclofenac gel.
Preservatives: Methylparaben, propylparaben, benzalkonium chloride.
---
10. Suspensions
Definition: Liquid dosage forms with finely divided insoluble particles suspended in a liquid vehicle.
Types
1. Oral suspensions β e.g., Amoxicillin suspension.
2. Topical suspensions β e.g., Calamine suspension.
3. Parenteral suspensions β e.g., Depot corticosteroid suspensions.
Preservatives: Sodium benzoate, parabens.
Suspending agents: Tragacanth, methylcellulose, sodium carboxymethylcellulose.
---
11. Emulsions
Definition: Two immiscible liquids stabilized by an emulsifying agent.
Types
1. Oil-in-water (O/W): oil droplets in water (used orally & topically).
2. Water-in-oil (W/O): water droplets in oil (greasy, protective).
Examples: Cod liver oil emulsion, Cream emulsions.
Emulsifying agents: Acacia, tragacanth, gelatin, Tween, Span.
Preservatives: Benzoic acid, parabens.
---
12. Solutions
Definition: Homogeneous liquid preparations where solutes are dissolved in a solvent.
Types
1. Aqueous solutions β e.g., Syrups, medicated waters.
2. Non-aqueous solutions β alcoholic, oily.
Examples: Lugolβs iodine, Potassium iodide solution.
Preservatives: Sodium benzoate, alcohol.
---
13. Spirits
Definition: Alcoholic solutions of volatile oils or aromatic substances.
Examples: Spirit of camphor, Spirit of peppermint.
---
14. Elixirs
Definition: Clear, sweetened hydro-alcoholic solutions for oral use.
Examples: Paracetamol elixir, Iron elixir.
Preservatives: Alcohol (self-preserving).
---
15. Tinctures
Definition: Alcoholic or hydro-alcoholic solutions prepared from plant or chemical substances.
Examples: Tincture of iodine, Tincture of benzoin.
---
16. Gargles & Mouthwashes
Gargles: Aqueous solutions for throat infections, not swallowed (e.g., Chlorhexidine gargle).
Mouthwashes: For cleansing and freshening the mouth (e.g., Listerine).
Preservatives: Alcohol, parabens, benzoates.
---
17. Enemas
Definition: Liquid preparations administered into the re**um.
Types:
Evacuant e***as (laxatives, e.g., Sodium phosphate).
Retention e***as (medicated, e.g., Barium e***a).
01/09/2025
π Comprehensive Note on Pharmaceutical Calculations
---
1. Introduction: Arabic Numerals
Arabic numerals are the numbers we commonly use: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9.
They replaced Roman numerals (I, II, III, IV, Vβ¦) because they are easier for calculation.
Example:
XIV (Roman) = 14 (Arabic)
XXI (Roman) = 21 (Arabic)
π In pharmacy, only Arabic numerals are used.
---
2. Systems of Measurement
(a) Metric System (most common)
Weight: gram (g), milligram (mg), kilogram (kg).
Volume: liter (L), milliliter (mL).
Length: meter (m), centimeter (cm), millimeter (mm).
Conversions:
1 g = 1000 mg
1 kg = 1000 g
1 L = 1000 mL
1 m = 100 cm = 1000 mm
Examples:
1. Convert 2500 mg to g β 2500 Γ· 1000 = 2.5 g
2. Convert 0.75 L to mL β 0.75 Γ 1000 = 750 mL
---
(b) Apothecary System (old, examiners love it)
Weight: grain (gr), ounce (oz), dram (Κ).
Volume: minim (β), fluid ounce (fl oz).
Conversions (approx):
1 grain = 65 mg
1 dram = 3.55 g
1 ounce = 28 g
Examples:
1. Convert 2 grains β 2 Γ 65 = 130 mg
2. Convert 3 drams β 3 Γ 3.55 = 10.65 g
---
(c) Household System
1 teaspoon (tsp) = 5 mL
1 tablespoon (tbsp) = 15 mL
1 cup = 240 mL
1 drop (gtt) β 0.05 mL
Examples:
1. 2 tsp syrup β 2 Γ 5 = 10 mL
2. 3 tbsp medicine β 3 Γ 15 = 45 mL
---
3. Ratio and Proportion
Used in drug strength and dose calculations.
Formula: a : b = c : d
Examples:
1. If 50 mL contains 200 mg, how much is in 80 mL?
= (200 Γ 80) Γ· 50 = 320 mg
2. If 100 mL contains 500 mg, how many mL contain 250 mg?
= (100 Γ 250) Γ· 500 = 50 mL
---
4. Percentage Strength
% w/v = g of solute in 100 mL solution
% w/w = g of solute in 100 g mixture
% v/v = mL of solute in 100 mL solution
Examples:
1. 5 g in 200 mL β (5 Γ 100 Γ· 200) = 2.5% w/v
2. 4 g in 50 g ointment β (4 Γ 100 Γ· 50) = 8% w/w
3. 20 mL alcohol in 200 mL β (20 Γ 100 Γ· 200) = 10% v/v
---
5. Ratio Strength
Expressed as 1 in X.
Examples:
1. 1:1000 β 1 g in 1000 mL β (1 Γ· 1000) Γ 100 = 0.1%
2. 1:200 β (1 Γ· 200) Γ 100 = 0.5%
3. 1:10,000 β (1 Γ· 10,000) Γ 100 = 0.01%
---
6. Dilution and Concentration
Formula: CβVβ = CβVβ
Examples:
1. How much 95% alcohol is needed to prepare 400 mL of 70%?
95 Γ Vβ = 70 Γ 400 β Vβ = 295 mL
2. 20 mL of 25% diluted to 100 mL β (20 Γ 25 Γ· 100) = 5%
---
7. Allegation Method
Mixing two concentrations to get a desired one.
Example: Make 500 mL of 30% alcohol using 20% and 50%.
High = 50, Low = 20, Desired = 30
Differences β 50β30 = 20; 30β20 = 10
Ratio = 20:10 = 2:1
Out of 3 parts, 2 parts 20% (333 mL), 1 part 50% (167 mL).
---
8. Dose Calculations
Clarkβs Rule (by weight): (Weight in lb Γ· 150) Γ Adult dose
Youngβs Rule (by age): (Age Γ· (Age + 12)) Γ Adult dose
Example: Adult dose = 300 mg, child = 50 lb
Clarkβs = (50 Γ· 150) Γ 300 = 100 mg
---
9. IV Infusion & Flow Rate
mL/hr = Volume Γ· Time
gtt/min = (Volume Γ Drop factor) Γ· Time in minutes
Example: 1000 mL in 8 hr using 20 gtt/mL set.
= (1000 Γ 20) Γ· (8 Γ 60) = 42 gtt/min
---
10. Isotonicity Adjustment
Ensures solutions are safe for eyes and injections.
Formula: NaCl equivalent = (0.9 Γ volume Γ· 100) β drug contribution.
---
11. Molarity, Molality, Normality
Molarity (M): Moles of solute Γ· Volume (L)
Molality (m): Moles of solute Γ· Mass of solvent (kg)
Normality (N): Equivalents Γ· Volume (L)
Example: 5 g NaOH (MW = 40) in 250 mL.
Moles = 5 Γ· 40 = 0.125
Molarity = 0.125 Γ· 0.25 = 0.5 M
---
12. Specific Gravity (SG)
= Weight of substance Γ· Weight of equal volume of water
Example: If SG = 1.2, then 100 mL weighs 120 g.
---
13. Displacement Value
Used in suppository preparation.
Example: Displacement value = 2 β 2 g drug displaces 1 g base.
---
β
Summary Table of Key Conversions
System Conversion
1 g 1000 mg
1 kg 1000 g
1 L 1000 mL
1 grain 65 mg
1 dram 3.55 g
1 ounce 28 g
1 tsp 5 mL
1 tbsp 15 mL
1 cup 240 mL
1 drop 0
30/08/2025
π Special senses sense Organs
Sense organs let us connect with the environment. They detect stimuli (light, sound, chemicals, touch) β change them into nerve impulses β brain interprets them.
---
ποΈ 1. Eye β Organ of Vision
Function: Detects light β creates vision.
Layers of the eye:
1. Fibrous layer
Sclera (white part, protection).
Cornea (clear window, bends light).
2. Vascular layer (uvea)
Choroid (blood supply).
Ciliary body (muscle β focuses lens, makes aqueous humor).
Iris (colored part, controls pupil size).
3. Retina (light-sensitive layer)
Rods β dim light, black/white.
Cones β bright light, color vision.
Macula & fovea β sharpest vision.
Optic nerve fibers β carry signals to brain.
Fluids:
Aqueous humor (front, nourishes).
Vitreous humor (back, keeps shape).
Accessory organs: eyelids, lashes, tears (lacrimal glands).
Nerve supply:
Optic nerve (CN II): vision to brain.
Oculomotor (CN III), Trochlear (CN IV), Abducens (CN VI): eye movement.
Trigeminal (CN V1): sensation of cornea (blinking reflex).
Brain area: Occipital lobe (visual cortex).
---
π 2. Ear β Organ of Hearing & Balance
Function: Hearing + balance.
Parts:
Outer ear: pinna + ear canal β collects sound.
Middle ear:
Ossicles (malleus, incus, stapes) β amplify sound.
Eustachian tube β equalizes air pressure.
Inner ear:
Cochlea β contains Organ of Corti (hair cells detect sound).
Vestibule (utricle & saccule) β detect straight movements.
Semicircular canals β detect rotations of head.
Nerve supply:
Vestibulocochlear nerve (CN VIII): hearing + balance.
Facial nerve (CN VII): supplies stapedius muscle in middle ear.
Brain area: Temporal lobe (auditory cortex) + cerebellum (balance).
---
π 3. Nose β Organ of Smell (Olfaction)
Function: Detects odor molecules.
Regions inside nose:
Vestibule (with hairs to filter).
Respiratory region (lined with cilia + mucus β warms, moistens air).
Olfactory region (roof of nasal cavity)
Olfactory epithelium: receptor neurons with cilia bind odor molecules.
Supporting cells & basal cells (regenerate).
Nerve supply:
Olfactory nerve (CN I): smell to brain.
Trigeminal nerve (CN V1 & V2): sense irritation (pepper, ammonia).
Brain area: Olfactory bulb β limbic system (emotions, memory) + olfactory cortex.
---
π
4. Tongue β Organ of Taste (Gustation)
Function: Taste, helps chewing, swallowing, speech.
Papillae types:
Fungiform: tip/sides, have taste buds.
Circumvallate: back, many taste buds.
Foliate: sides, active in children.
Filiform: no taste buds, give rough texture.
Taste buds: contain receptor cells (detect dissolved chemicals).
5 primary tastes: sweet, salty, sour, bitter, umami.
Nerve supply:
Facial nerve (CN VII): anterior 2/3 taste.
Glossopharyngeal nerve (CN IX): posterior 1/3 taste.
Vagus nerve (CN X): taste from root + epiglottis.
Trigeminal nerve (CN V): general touch/temperature/pain sensation of tongue.
Brain area: Gustatory cortex (insula & frontal lobe).
---
π€² 5. Skin β Organ of Touch
Function: Touch, pressure, vibration, temperature, pain.
Layers of skin:
1. Epidermis (outer)
Stratum corneum β dead keratinized cells.
Stratum lucidum β only thick skin (palms, soles).
Stratum granulosum β keratohyalin.
Stratum spinosum β strength, flexibility.
Stratum basale β stem cells, melanocytes (color), Merkel cells (touch).
2. Dermis (middle)
Papillary layer (loose CT, Meissner corpuscles β light touch).
Reticular layer (dense CT, Pacinian corpuscles β pressure, Ruffini β stretch).
3. Hypodermis (subcutaneous fat layer, cushions, insulates).
Receptors:
Free nerve endings β pain & temperature.
Meissner corpuscles β light touch.
Merkel discs β fine touch/texture.
Pacinian corpuscles β deep pressure, vibration.
Ruffini endings β skin stretch.
Nerve supply: Sensory nerves from spinal nerves (dermatomes) β spinal cord β brain.
Brain area: Parietal lobe (somatosensory cortex).
---
π Extra Senses
1. Balance: Inner ear (utricle, saccule, semicircular canals), nerve = CN VIII.
2. Temperature (Thermoreception): Free nerve endings in skin + hypothalamus, via spinal nerves.
3. Pain (Nociception): Free nerve endings, via spinal nerves + cranial nerves (like trigeminal).
4. Proprioception (Position sense): From muscle spindles, tendons, joints β spinal nerves β cerebellum & parietal lobe.
---
β
Final Quick Recap (Organ β Parts β Nerves β Brain Area)
Eye: cornea, lens, retina β Optic nerve (CN II) β occipital lobe.
Ear: cochlea, vestibule, canals β Vestibulocochlear (CN VIII) β temporal lobe/cerebellum.
Nose: olfactory epithelium β Olfactory nerve (CN I) β olfactory cortex + limbic system.
Tongue: papillae, taste buds β CN VII, IX, X β gustatory cortex.
Skin: epidermis, dermis receptors β spinal nerves β parietal lobe.
28/08/2025
DIABETES AND ANTIDIABETES*
*πΉ Diabetes Mellitus*
1. Definition
Diabetes mellitus is a chronic metabolic disease in which the body cannot regulate blood glucose properly. It happens because of problems with insulin, which is the hormone responsible for moving glucose into cells.
If insulin is not produced enough, or
If the body does not respond well to insulin (insulin resistance),
blood glucose remains high (hyperglycemia).
2. Types of Diabetes
1. Type 1 Diabetes Mellitus
The immune system destroys the pancreatic beta cells that make insulin.
The body produces no insulin at all.
Seen mostly in children and young adults, usually lean body type.
Treatment: Insulin therapy for life.
2. Type 2 Diabetes Mellitus
The most common type (more than ninety percent of cases).
Combination of insulin resistance and reduced insulin secretion.
Strongly linked with obesity, family history, and sedentary lifestyle.
Treatment: lifestyle modification, oral antidiabetic drugs, sometimes insulin.
3. Gestational Diabetes
Occurs during pregnancy due to hormonal changes that make cells resistant to insulin.
Usually disappears after delivery, but increases risk of developing Type 2 diabetes later.
4. Other Specific Types
Diabetes due to pancreatic disease (for example pancreatitis, pancreatic cancer).
Drug induced (for example long-term steroid use).
Genetic defects of insulin action or secretion.
3. Complications of Diabetes
Acute complications:
Diabetic ketoacidosis (mainly in Type 1).
Hyperosmolar hyperglycemic state (mainly in Type 2).
Chronic complications:
Microvascular: damage to small vessels causing retinopathy (eye disease), nephropathy (kidney disease), neuropathy (nerve disease).
Macrovascular: damage to large vessels causing heart attack, stroke, peripheral vascular disease.
*πΉ Antidiabetic Drugs*
1. Insulin
The only treatment for Type 1 diabetes and used in severe Type 2 diabetes, gestational diabetes, and emergencies.
Mechanism of action:
Binds to insulin receptors in muscle and fat β increases glucose uptake.
Decreases glucose production by the liver.
Promotes storage of glucose as glycogen.
Types according to duration:
Rapid acting: Lispro, Aspart, Glulisine.
Short acting: Regular insulin.
Intermediate acting: NPH (Neutral Protamine Hagedorn).
Long acting: Glargine, Detemir, Degludec.
Side effects: hypoglycemia (low blood sugar), weight gain.
2. Biguanides
Example: Metformin.
First-line drug for Type 2 diabetes.
Mechanism of action:
Decreases glucose production by the liver.
Increases insulin sensitivity in muscle and fat.
Reduces absorption of glucose from the intestine.
Advantages: no hypoglycemia, weight neutral or slight weight loss, protects the heart and kidneys.
Side effects: stomach upset, metallic taste, rare but serious lactic acidosis.
Avoid in patients with severe kidney disease.
3. Sulfonylureas
Examples: Glibenclamide, Glipizide, Glimepiride.
Mechanism of action: stimulate the pancreas to release more insulin by blocking potassium channels in beta cells.
Side effects: hypoglycemia, weight gain.
4. Meglitinides
Examples: Repaglinide, Nateglinide.
Mechanism of action: same as sulfonylureas, stimulate insulin release, but act for a shorter duration.
Best use: control of blood glucose after meals.
Side effects: hypoglycemia (less than sulfonylureas).
5. Thiazolidinediones (Glitazones)
Examples: Pioglitazone, Rosiglitazone.
Mechanism of action: activate a nuclear receptor called PPAR-gamma β increase insulin sensitivity in fat and muscle, reduce glucose output by the liver.
Side effects: weight gain, fluid retention, risk of heart failure, bone fractures.
6. Alpha-glucosidase Inhibitors
Examples: Acarbose, Miglitol.
Mechanism of action: block enzymes in the intestine that break down complex carbohydrates β slow digestion and absorption of glucose β lower rise of blood glucose after meals.
Side effects: bloating, flatulence, diarrhea.
7. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Examples: Sitagliptin, Saxagliptin, Linagliptin.
Mechanism of action: inhibit the enzyme DPP-4 which breaks down incretin hormones (GLP-1, GIP). Incretins stimulate insulin release and reduce glucagon.
Effect: increase insulin secretion in a glucose-dependent way, lower glucagon, moderate blood glucose lowering.
Side effects: mild infections, rare pancreatitis.
8. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Examples: Exenatide, Liraglutide, Semaglutide.
Given by injection.
Mechanism of action: mimic natural GLP-1 β increase insulin secretion, reduce glucagon, slow stomach emptying, increase satiety.
Advantages: weight loss, good for heart and kidneys.
Side effects: nausea, vomiting, pancreatitis.
9. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Examples: Dapagliflozin, Empagliflozin, Canagliflozin.
Mechanism of action: block SGLT2 in the kidney β prevent reabsorption of glucose β glucose is excreted in urine.
Advantages: weight loss, lower blood pressure, protect the heart and kidneys.
Side effects: ge***al infections (fungal), dehydration, rare diabetic ketoacidosis.
10. Amylin Analogues
Example: Pramlintide.
Used with insulin in both Type 1 and Type 2.
Mechanism of action: decreases glucagon secretion, slows stomach emptying, increases satiety.
Side effects: nausea, risk of hypoglycemia when combined with insulin.
*πΉ Non-drug Management*
Diet: balanced, high in fiber, low in refined sugar.
Exercise: improves insulin sensitivity.
Weight loss: especially important in Type 2 diabetes.
*πΉ Summary*
Type 1 diabetes β always needs insulin.
Type 2 diabetes β start with lifestyle + Metformin, add other drugs based on patientβs condition.
Modern drugs (GLP-1 agonists, SGLT2 inhibitors) β best for patients with heart or kidney problems, and for weight loss.
Choice of drug depends on patient age, weight, risk of hypoglycemia, organ function, and comorbid diseases.
[8/28, 7:32 PM] Pharm.Ahmad: *πΉ Diabetes Insipidus (DI)*
1. Definition
Diabetes insipidus is a disorder of water balance where the kidneys cannot concentrate urine properly, leading to excessive urination (polyuria) and excessive thirst (polydipsia).
Unlike diabetes mellitus, it has nothing to do with blood sugar.
The name βinsipidusβ means tasteless (urine is dilute and not sweet, unlike the βmellitusβ form which is sweet).
2. Types of Diabetes Insipidus
1. Central Diabetes Insipidus (Neurogenic DI)
Cause: The brain (hypothalamus or posterior pituitary) does not produce enough antidiuretic hormone (ADH, also called vasopressin).
Common causes: head injury, pituitary surgery, brain tumor, infections, genetic defects.
2. Nephrogenic Diabetes Insipidus
Cause: Kidneys do not respond to ADH, even though the hormone is present.
Causes: genetic defects, chronic kidney disease, certain drugs (lithium, demeclocycline).
3. Gestational Diabetes Insipidus
Occurs during pregnancy due to destruction of ADH by placental enzymes (vasopressinase).
Usually temporary and resolves after delivery.
4. Dipsogenic Diabetes Insipidus (Primary Polydipsia)
Cause: Abnormal thirst mechanism in the hypothalamus β excessive fluid intake suppresses ADH secretion.
Common in psychiatric illness or brain damage.
3. Pathophysiology (What goes wrong)
Normally, ADH acts on the kidneyβs collecting ducts to increase water reabsorption β making urine concentrated.
In DI, either ADH is absent (central) or kidneys do not respond to it (nephrogenic) β urine cannot be concentrated β large amounts of dilute urine are produced.
4. Symptoms
Polyuria (very large urine volume, up to 10β20 liters/day).
Polydipsia (excessive thirst, preference for cold water).
Nocturia (frequent urination at night).
Dehydration signs: dry mouth, low blood pressure, weight loss.
In children: irritability, bed-wetting, poor growth.
5. Diagnosis
1. Urine tests:
Very dilute urine (low specific gravity, low osmolality).
No glucose in urine.
2. Water deprivation test:
Patient is not allowed to drink water β in normal people urine becomes concentrated.
In DI, urine stays dilute.
3. Desmopressin (ADH) test:
After giving synthetic ADH:
If urine concentrates β Central DI (problem was lack of ADH).
If urine does not change β Nephrogenic DI (kidneys not responding).
6. Treatment
*πΈ Central Diabetes Insipidus*
Desmopressin (DDAVP): synthetic ADH, given as nasal spray, oral tablets, or injection.
Adequate hydration.
Treat underlying cause (tumor, trauma, infection).
*πΈ Nephrogenic Diabetes Insipidus*
Desmopressin is not effective.
Low-salt diet + plenty of fluids.
Thiazide diuretics (paradoxically reduce urine volume by increasing sodium excretion β mild dehydration β increases water reabsorption in proximal tubules).
Amiloride (potassium-sparing diuretic) especially useful if cause is lithium therapy.
*πΈ Gestational Diabetes Insipidus*
Desmopressin (safe in pregnancy).
Usually resolves after childbirth.
*πΈ Dipsogenic Diabetes Insipidus*
Difficult to treat.
Behavioral therapy, limiting water intake, sometimes low-dose desmopressin.
7. Complications if Untreated
Severe dehydration.
Electrolyte imbalance (especially high sodium = hypernatremia).
Shock in extreme cases.
*πΉ Summary*
Diabetes insipidus = βwater diabetes,β caused by ADH problems, not blood sugar.
Types: Central (low ADH), Nephrogenic (kidneys resist ADH), Gestational, Dipsogenic.
Symptoms: extreme urination and thirst with dilute urine.
*Treatment:*
Central β Desmopressin.
Nephrogenic β thiazide diuretics, amiloride, low-salt diet.
Gestational β desmopressin.
Dipsogenic β behavioral measures.
28/08/2025
ANTINEOPLASTIC (ANTI-CANCER) MEDICATIONS β SUMMARY NOTES
1. Definition
Antineoplastic (anticancer, chemotherapy) drugs are agents that kill or inhibit the growth of malignant (cancerous) cells.
They work by interfering with cell division (mitosis), DNA synthesis, or cell metabolism since cancer cells divide rapidly.
---
2. General Principles
Target rapidly dividing cells (cancer cells), but also affect normal fast-dividing cells β bone marrow, GI tract, hair follicles.
Often used in combinations to increase effectiveness and reduce resistance.
Treatment may be curative, palliative, or adjuvant (after surgery/radiotherapy).
---
3. Classification of Antineoplastic Drugs
A. Alkylating agents
Mechanism: Add alkyl groups to DNA β cross-linking β prevents replication.
Examples: Cyclophosphamide, Ifosfamide, Melphalan.
Side effects: Bone marrow suppression, hemorrhagic cystitis (esp. cyclophosphamide).
B. Antimetabolites
Mechanism: Mimic normal metabolites β block DNA/RNA synthesis.
Examples:
Methotrexate (folate antagonist).
5-Fluorouracil (pyrimidine analog).
6-Mercaptopurine (purine analog).
Side effects: Myelosuppression, mucositis, hepatotoxicity.
C. Antitumor antibiotics
Mechanism: Intercalate into DNA, block RNA synthesis, produce free radicals.
Examples: Doxorubicin, Daunorubicin, Bleomycin.
Side effects:
Cardiotoxicity (doxorubicin).
Pulmonary fibrosis (bleomycin).
D. Plant alkaloids (mitotic inhibitors)
Mechanism: Disrupt microtubules β prevent mitosis.
Subclasses:
Vinca alkaloids (Vincristine, Vinblastine) β inhibit microtubule formation.
Taxanes (Paclitaxel, Docetaxel) β stabilize microtubules (no disassembly).
Side effects:
Neurotoxicity (vincristine).
Myelosuppression.
E. Topoisomerase inhibitors
Mechanism: Block topoisomerase enzymes β DNA breaks.
Examples:
Topoisomerase I inhibitors: Irinotecan, Topotecan.
Topoisomerase II inhibitors: Etoposide, Teniposide.
Side effects: Severe myelosuppression, diarrhea (esp. irinotecan).
F. Hormonal agents
Mechanism: Modify hormone environment (since some cancers are hormone-dependent).
Examples:
Tamoxifen (anti-estrogen for breast cancer).
Flutamide (anti-androgen for prostate cancer).
Aromatase inhibitors (Letrozole, Anastrozole).
Side effects: Thrombosis, hot flashes, osteoporosis.
G. Targeted therapy
Act on specific molecular targets in cancer cells.
Examples:
Imatinib (tyrosine kinase inhibitor, used in CML).
Trastuzumab (monoclonal antibody against HER2 in breast cancer).
Side effects: Less toxic to normal cells, but may cause cardiotoxicity (trastuzumab).
H. Immunotherapy (biologic agents)
Boost immune system to fight cancer.
Examples: Interleukins, Interferons, Immune checkpoint inhibitors (Nivolumab, Pembrolizumab).
Side effects: Autoimmune-like reactions (colitis, thyroiditis).
I. Platinum compounds
Mechanism: Form DNA cross-links similar to alkylating agents.
Examples: Cisplatin, Carboplatin, Oxaliplatin.
Side effects:
Nephrotoxicity (cisplatin).
Ototoxicity.
Peripheral neuropathy.
---
4. Pharmacokinetics
Administered mostly IV, some oral.
Many have narrow therapeutic index.
Metabolized in liver, excreted by kidney.
Dose adjustment required in organ dysfunction.
---
5. Adverse Effects (General for Most)
Bone marrow suppression β anemia, leukopenia, thrombocytopenia (major dose-limiting toxicity).
GI effects β nausea, vomiting, diarrhea, mucositis.
Alopecia (hair loss).
Infections due to immunosuppression.
Secondary cancers (due to DNA damage).
---
6. Resistance
Cancer cells can resist by:
Increased drug efflux (P-glycoprotein pump).
Altered drug targets.
Enhanced DNA repair.
Drug inactivation.
Solution: combination therapy and new targeted drugs.
---
7. Clinical Use
Solid tumors (breast, lung, colon, ovarian, prostate).
Hematological cancers (leukemias, lymphomas, multiple myeloma).
As adjuvant, neoadjuvant, or palliative therapy.
---
β
In summary:
Antineoplastic drugs are used to treat cancers by disrupting cell division, DNA synthesis, or hormone signaling. They are grouped into alkylating agents, antimetabolites, antibiotics, plant alkaloids, topoisomerase inhibitors, hormonal agents, platinum compounds, targeted therapies, and immunotherapies. Their main challenge is toxicity to normal cells and resistance development, hence combination therapy and careful monitoring are essential.
Click here to claim your Sponsored Listing.